Peptide Lab HQ Research Guide
Retatrutide Research Guide
A research-focused compound profile covering Retatrutide identity, triple-receptor pathway research, laboratory reference data, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Retatrutide |
|---|---|
| Research Code | LY3437943 |
| Compound Type | Synthetic multi-receptor peptide agonist |
| CAS Number | 2381089-83-2 |
| Amino Acid Length | 39 amino acids with structural modifications |
| Research Category | GIP, GLP-1, and glucagon receptor pathway research |
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | Approximately 4731 g/mol |
| Appearance | White to off-white lyophilized powder |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Retatrutide is commonly discussed in research involving triple-receptor pathway activation, incretin biology, metabolic signaling, glucagon receptor activity, and controlled study models related to body-weight, glycemic, hepatic, and cardiometabolic endpoints.
Triple-Receptor Research
Retatrutide is studied as a single molecule designed to activate GIP, GLP-1, and glucagon receptor pathways in controlled research settings.
Incretin Pathway Models
Used in research models exploring incretin signaling, metabolic regulation, insulin-related signaling, and nutrient-response pathways.
Glucagon Receptor Studies
Relevant to research involving glucagon receptor activity, energy-expenditure modeling, hepatic signaling, and substrate utilization.
Body-Weight Research Models
Appears in clinical and preclinical research discussions involving controlled body-weight, appetite, and energy-balance endpoints.
Glycemic Control Research
Studied in research models involving glucose regulation, A1C-related endpoints, and type 2 diabetes clinical-trial populations.
Hepatic & Cardiometabolic Research
Being evaluated in broader clinical research areas including metabolic dysfunction-associated steatotic liver disease and cardiovascular or renal outcomes.
Research Scope
These applications are provided for educational and research-reference purposes only. Retatrutide remains an investigational compound and has not been approved by regulatory agencies for public use.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 5 mg Retatrutide |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 2.5 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 2.5 mg/mL, 1 unit equals 0.025 mg / 25 mcg Retatrutide. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear. Do not shake!
- For higher-concentration preparations, verify that the material is fully dissolved before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Retatrutide, also referenced as LY3437943 | Retatrutide is commonly discussed as a multi-receptor incretin-pathway research compound with activity studied across GLP-1, GIP, and glucagon receptor signaling contexts. |
| Triple-Receptor Research Context | GLP-1 / GIP / glucagon receptor pathway context | Commonly discussed in receptor-signaling, incretin-pathway, glucagon-pathway, metabolic-marker, and energy-balance research contexts. |
| Metabolic Research Context | Clinical-study context only | Retatrutide has been discussed in clinical-study contexts involving body-weight, glycemic, lipid, liver-fat, appetite, and cardiometabolic marker observations. These clinical-study references are not research-chemical dosing standards. |
| Glucose / Insulin Marker Research | Model-dependent endocrine-marker tracking | Commonly discussed in glucose-handling, insulin-response, incretin-response, appetite-regulation, and metabolic-homeostasis research models. |
| Liver / Lipid Marker Research | Experimental and clinical-marker context | Retatrutide-related research is often discussed in liver-fat, triglyceride, lipid-marker, hepatic-metabolism, and metabolic-disease model contexts. |
| Public Protocol-Style Reference | Milligram-range reference examples | Public protocol-style references commonly describe Retatrutide in milligram-range examples. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
| 15 mg | 3.0 mL | 5 mg/mL |
| 20 mg | 3.0 mL | 6.67 mg/mL |
| 30 mg | 3.0 mL | 10 mg/mL |
| 40 mg | 3.0 mL | 13.33 mg/mL |
| 50 mg | 3.0 mL | 16.67 mg/mL |
| 60 mg | 3.0 mL | 20 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 2.5 mg/mL | U-100 Unit Reference | Approx. References per 5 mg Vial |
|---|---|---|---|
| 0.1 mg / 100 mcg | 0.04 mL | 4 units | 50 |
| 0.25 mg / 250 mcg | 0.10 mL | 10 units | 20 |
| 0.5 mg / 500 mcg | 0.20 mL | 20 units | 10 |
| 1 mg / 1000 mcg | 0.40 mL | 40 units | 5 |
| 2 mg / 2000 mcg | 0.80 mL | 80 units | 2.5 |
| 4 mg / 4000 mcg | 1.60 mL | 160 units | 1.3 |
| 8 mg / 8000 mcg | 3.20 mL | 320 units | 0.6 |
| 10 mg / 10000 mcg | 4.00 mL | 400 units | 0.5 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Low Conversion Reference | Calculation reference only | 0.1 mg reference amount | 4 units / 0.04 mL |
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.25 mg reference amount | 10 units / 0.10 mL |
| Low-to-Mid Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 20 units / 0.20 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 40 units / 0.40 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 80 units / 0.80 mL |
| Upper Conversion Example | Calculation reference only | 4 mg reference amount | 160 units / 1.60 mL |
| High Conversion Example | Calculation reference only | 8 mg reference amount | 320 units / 3.20 mL |
| Preparation-Level Conversion Example | Calculation reference only | 10 mg reference amount | 400 units / 4.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for receptor-signaling, incretin-pathway, glucagon-pathway, cellular-response, or pathway-marker documentation depending on the model. |
| Acute Metabolic Observation Window | Single session to several days | Used for short-term glucose, appetite, endocrine-marker, receptor-response, or early pathway tracking depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for early controlled observation involving glucose-handling markers, appetite-response markers, metabolic markers, or dose-ranging model documentation. |
| Standard Protocol-Style Window | 4–12 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 12–24 weeks or longer | Used when longer documentation is needed for body-weight, liver-fat, lipid-marker, glycemic-marker, cardiometabolic, or follow-up marker tracking. |
| Follow-Up / Washout | 4–12 weeks | Used to document post-study observations, marker return, delayed response patterns, or return-to-baseline data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Retatrutide, also referenced as LY3437943, is commonly discussed in GLP-1, GIP, glucagon receptor, incretin-pathway, metabolic-marker, glycemic-marker, appetite-response, liver-fat, lipid-marker, body-weight, and cardiometabolic research contexts. The selector above updates calculations for 5 mg and 10 mg vial references reconstituted with 2.0 mL bacteriostatic water, and 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg vial references reconstituted with 3.0 mL bacteriostatic water. Published study references, clinical-study contexts, and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Retatrutide is commonly discussed in research involving triple GIP / GLP-1 / glucagon receptor activity, body-weight reduction, HbA1c response, appetite signaling, liver-fat reduction, lipid markers, blood-pressure markers, and metabolic pathway regulation.
Study Limitations
Retatrutide remains investigational. Research findings should be interpreted according to study phase, population, receptor biology, dose-escalation design, metabolic status, study duration, and endpoint selection.
Safety Considerations
Research discussion should account for gastrointestinal response, nausea, vomiting, diarrhea, constipation, appetite suppression, glucose-marker changes, heart-rate observations, gallbladder or pancreatic safety context, peptide purity, sterility documentation, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.